Reconstructive conundrums in the era of pembrolizumab treatment for breast cancer: A case series review
Journal of Plastic, Reconstructive & Aesthetic Surgery · 2026-08 · 119 · 114-118
DOI: 10.1016/j.bjps.2026.02.015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Plastic, Reconstructive & Aesthetic Surgery, 2026-08. Verfasst von Lily Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic & Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Mammaplasty, Triple Negative Breast Neoplasms. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Pembrolizumab, commercially known as Keytruda, is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1). Its popularity increased after the KEYNOTE-522 trial demonstrated a statistically significant increase in pathologic complete response compared to placebo in early-stage triple-negative breast cancer patients. This led to global regulatory approvals and a subsequent surge in clinical utilization. Despite the positive outcomes in clinical trials, there is a paucity of information concerning its influence on perioperative and postoperative outcomes, particularly during breast reconstruction. This manuscript offers a concise review of adverse events linked to pembrolizumab and similar immunotherapies. We detail a case series of five patients post-pembrolizumab treatment who underwent breast reconstruction and encountered unforeseen complications, such as thyroid dysregulation, cardiac failure, and epidermolysis. Given the increased use of immunotherapies in breast cancer care, understanding the impact of these adverse effects on surgical outcomes is crucial for optimizing patient care in breast cancer reconstruction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic & Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Plastic & Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: kbroder4@jhmi.edu.
Zitieren
APA
Zhu, L., Khong, J., Heron, M. J., Zhu, K. J., Pinnock, N., Mundy, L. R., Habibi, M., & Broderick, K. P. (2026). Reconstructive conundrums in the era of pembrolizumab treatment for breast cancer: A case series review. Journal of Plastic, Reconstructive & Aesthetic Surgery, 119, 114-118. https://doi.org/10.1016/j.bjps.2026.02.015
Vancouver
Zhu L, Khong J, Heron MJ, Zhu KJ, Pinnock N, Mundy LR, et al. Reconstructive conundrums in the era of pembrolizumab treatment for breast cancer: A case series review. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2026;119:114-118. doi:10.1016/j.bjps.2026.02.015
BibTeX
@article{Zhu2026,
author = {Zhu, Lily and Khong, Jeffrey and Heron, Matthew J and Zhu, Katherine J and Pinnock, Nahstajia and Mundy, Lily R and Habibi, Mehran and Broderick, Kristen P},
title = {Reconstructive conundrums in the era of pembrolizumab treatment for breast cancer: A case series review},
journal = {Journal of Plastic, Reconstructive & Aesthetic Surgery},
year = {2026},
volume = {119},
pages = {114--118},
doi = {10.1016/j.bjps.2026.02.015}
}
EUVIMED